Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 30, 2025 17:00 ET | Source: Aptose Biosciences, Inc.

Aptose Announces Deferral of Interest Payment

Aptose Announces Deferral of Interest Payment
June 20, 2025 07:52 ET | Source: Aptose Biosciences, Inc.

Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML

Aptose and Hanmi Pharmaceutical Enter New Loan Agreement to Continue Development of Tuspetinib in Triplet Therapy for AML
June 17, 2025 07:45 ET | Source: Aptose Biosciences, Inc.

Aptose Provides Corporate Updates

Aptose announces corporate updates
June 12, 2025 12:00 ET | Source: Aptose Biosciences, Inc.

Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress

Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2
May 27, 2025 17:53 ET | Source: Aptose Biosciences, Inc.

Aptose Announces Results from Annual and Special Meeting of Shareholders

Aptose Announces Results from Annual and Special Meeting of Shareholders
May 20, 2025 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee

Aptose Announces Positive CSRC Approval to Dose Escalate to 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline AML
May 14, 2025 13:07 ET | Source: Aptose Biosciences, Inc.

Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress

Aptose Selected for Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at EHA2025
May 08, 2025 07:00 ET | Source: Aptose Biosciences, Inc.

Aptose Reports First Quarter 2025 Results

Aptose Reports First Quarter 2025 Results; Highlights Progress in TUSCANY Clinical Trial of Tuspetinib in AML Triple Frontline Therapy
May 05, 2025 07:00 ET | Source: Aptose Biosciences, Inc.

Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial

Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial
April 23, 2025 17:00 ET | Source: Aptose Biosciences, Inc.

Aptose Announces Auditor Not Standing for Re-Appointment

Aptose Announces Auditor Not Standing for Re-Appointment